Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry

ConclusionsMore than 50% of RMS switched therapy due to disease activity. HE DMTs, especially anti-CD20 drugs, significantly reduce the risk of treatment switch.

http://link.springer.com/10.1007/s00415-023-12137-8

Source: Journal of Neurology - December 22, 2023 Category: Neurology Source Type: research